TY - JOUR
T1 - The metabolic effects of omega-3 plant sterol esters in mixed hyperlipidemic subjects
AU - Bitzur, Rafael
AU - Cohen, Hofit
AU - Cohen, Tzafra
AU - Dror, Tali W.
AU - Herzog, Yael
AU - Lifshitz, Yael
AU - Lubish, Tamar
AU - Harats, Dror
AU - Rubinstein, Ardon
N1 - Funding Information:
The study was supported by Enzymotec Ltd., Migdal HaEmeq, Israel. R.Bitzur(*).H.Cohen.T.Lubish.D.Harats The Bert W. Strassburger Lipid Center, Sheba Medical Center, Tel Hashomer, Israel e-mail: [email protected]
PY - 2010/12
Y1 - 2010/12
N2 - Purpose: The aim of the current study was to evaluate the therapeutic effects of omega-3 plant sterol esters (n-3-PSE) on lipid profile and other coronary heart disease risk factors in subjects with mixed hyperlipidemia. Methods: Ninety-one patients with mixed hyperlipidemia were randomized in a double blind fashion to receive either placebo (corn oil) or n-3-PSE. Twenty four patients dropped out or were excluded from the efficacy analysis due to protocol violation. The primary efficacy endpoint was mean change in plasma low-density lipoprotein cholesterol (LDL-C) levels after 12 weeks of treatment. Other efficacy measures included plasma lipids, lipoproteins, and high-sensitivity C-reactive protein (hsCRP) levels. Participants who completed the double-blind study were given the option to continue into an open-label, 12-weeks follow up phase. Results: n-3-PSE treatment did not result in a significant change in LDL-C levels. Triglyceride levels were reduced significantly by 19% (51 mg/dL, p<0.0001) in the n-3-PSE group in comparison with the placebo group (p=0.025). Diastolic blood pressure and hsCRP were reduced by 7% (5.9 mmHg) and 7.8% (0.6 mg/L), respectively, and were significantly different from the placebo group (p=0.036 and p=0.018, respectively). Conclusions: In patients with mixed hyperlipidemia, n-3-PSE treatment may offer a safe and effective therapy for triglyceride level reduction while avoiding the typical increase in LDL-C levels associated with n-3 fatty acid treatment. The observed reduction in blood pressure and inflammation markers warrants further evaluation. The positive effect of n-3-PSE treatment was preserved at the end of the follow up phase.
AB - Purpose: The aim of the current study was to evaluate the therapeutic effects of omega-3 plant sterol esters (n-3-PSE) on lipid profile and other coronary heart disease risk factors in subjects with mixed hyperlipidemia. Methods: Ninety-one patients with mixed hyperlipidemia were randomized in a double blind fashion to receive either placebo (corn oil) or n-3-PSE. Twenty four patients dropped out or were excluded from the efficacy analysis due to protocol violation. The primary efficacy endpoint was mean change in plasma low-density lipoprotein cholesterol (LDL-C) levels after 12 weeks of treatment. Other efficacy measures included plasma lipids, lipoproteins, and high-sensitivity C-reactive protein (hsCRP) levels. Participants who completed the double-blind study were given the option to continue into an open-label, 12-weeks follow up phase. Results: n-3-PSE treatment did not result in a significant change in LDL-C levels. Triglyceride levels were reduced significantly by 19% (51 mg/dL, p<0.0001) in the n-3-PSE group in comparison with the placebo group (p=0.025). Diastolic blood pressure and hsCRP were reduced by 7% (5.9 mmHg) and 7.8% (0.6 mg/L), respectively, and were significantly different from the placebo group (p=0.036 and p=0.018, respectively). Conclusions: In patients with mixed hyperlipidemia, n-3-PSE treatment may offer a safe and effective therapy for triglyceride level reduction while avoiding the typical increase in LDL-C levels associated with n-3 fatty acid treatment. The observed reduction in blood pressure and inflammation markers warrants further evaluation. The positive effect of n-3-PSE treatment was preserved at the end of the follow up phase.
KW - Dyslipidemia
KW - High-sensitivity C-reactive protein (hsCRP)
KW - Hypertriglyceridemia
KW - Plant sterol esters
KW - n-3 fatty acids
UR - http://www.scopus.com/inward/record.url?scp=79958204676&partnerID=8YFLogxK
U2 - 10.1007/s10557-010-6249-5
DO - 10.1007/s10557-010-6249-5
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:79958204676
SN - 0920-3206
VL - 24
SP - 429
EP - 437
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
IS - 5-6
ER -